Pembrolizumab in Combination With Lenvatinib in Pts With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.
Recurrent Vulvar Cancer|Persistent Vulvar Cancer|Metastatic Vulva Cancer|Locally Advanced Vulvar Cancer
DRUG: Pembrolizumab|DRUG: Lenvatinib
ORR within 24 weeks, ORR will be defined as the proportion of patients with PR or CR within 24 weeks starting with the first study treatment. Tumor responses will be assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST 1.1), 24 weeks
Evaluate the efficacy of lenvatinib + pembrolizumab in terms of overall ORR, Overall ORR, From date of starting study treatment until the date of first documented progression or date of death from any cause, whichever occurs earlier, assessed up to 40 months|Evaluate the efficacy of lenvatinib + pembrolizumab in terms of disease control rate (DCR), DCR will be defined as the proportion of patients with PR, CR or stable disease (SD), For 8 weeks|Evaluate the efficacy of lenvatinib + pembrolizumab in terms of duration of response (DOR), DOR will be defined as time from response until first progression or death, whichever occurs first, Time from response until first progression or death, whichever occurs first, assessed up to 40 months|Evaluate the efficacy of lenvatinib + pembrolizumab in terms of overall survival (OS), OS will be defined as the time from date of starting study treatment to death., Time from date of starting study treatment to death, assessed up to 40 months|Evaluate the efficacy of lenvatinib + pembrolizumab in terms of progression free survival (PFS), PFS will be defined as the time from starting study treatment to progressive disease (PD) or death, whichever occurs first, Time from starting study treatment to progressive disease or death, whichever occurs first, assessed up to 40 months|Evaluate the efficacy of lenvatinib + pembrolizumab in terms of time to first subsequent therapy (TFST), • TFST will be defined as the time from date of starting study treatment until the start of the first subsequent therapy or death whichever occurs first., The time from date of starting study treatment until the start of the first subsequent therapy or death whichever occurs first, assessed up to 40 months|Evaluate the efficacy of lenvatinib + pembrolizumab in terms of time to second subsequent therapy (TSST), • TSST will be defined as the time from date of starting study treatment until the start of second subsequent treatment or death whichever occurs first., Time from date of starting study treatment until the start of second subsequent treatment or death whichever occurs first, assessed up to 40 motnhs|Patient reported outcomes (QLQ), Quality of life is measured by patient reported outcome instruments EORTC QLQ C-30 to evaluate the efficacy of combination of lenvatinib and pembrolizumab, Assessed frequently during the trial up to 40 months|Patient reported outcomes (QLQ), Quality of life is measured by patient reported outcome instruments EORTC QLQ VU34 to evaluate the efficacy of combination of lenvatinib and pembrolizumab, Assessed frequently during the trial up to 40 months|Number of participants with treatment-related adverse events (AE) and/or serious adverse events (SAEs) and/or AEs that led to premature withdrawal of trial treatment and/or interruptions/dose modifications, Graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, to evaluate the safety and tolerability of the combination of lenvatinib and pembrolizumab, At every visit during the trial up to safety follow, thereafter up to 120 days after administration of last dose of study medication
A multicenter, single-arm phase II, open-label study, to evaluate the efficacy and safety of pembrolizumab 400 mg Q6W in combination with lenvatinib 20 mg QD in patients with recurrent, persistent, metastatic or locally advanced VSCC not amenable to salvage surgery or definitive (chemo)radiation.